Nebenwirkungen · Lucentis
Lucentis 10 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-116988 · Präparat HOS-094515
The safety of Lucentis 0.2 mg was studied in a 6-month clinical study (RAINBOW), which included 73 preterm infants with ROP treated with ranibizumab 0.2 mg (see section 5.1). Ocular adverse reactions reported in more than one patient treated with ranibizumab 0.2 mg were retinal haemorrhage and conjunctival haemorrhage. Non-ocular adverse reactions reported in more than one patient treated with ranibizumab 0.2 mg were nasopharyngitis, anaemia, cough, urinary tract infection and allergic reactions. Adverse reactions established for adult indications are considered applicable to preterm infants with ROP, though not all were observed in the RAINBOW study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:52:00Z · SHA-256 99f5c71aa34ea0289059cf6afa389329036ec0035d42e5a4cfeaefbb65a1300c · Passage ebc7663d4439b2dd588d5cbd65037b0517c9e29e11e0d1662e78195e86f9b356 · Zeichen 5484–6143 im Abschnitt